Quality is in our DNA

Welcome to Sonic Healthcare USA

Sonic Healthcare USA is a division of Sonic Healthcare Limited, one of the  largest diagnostic laboratory medicine companies in the world. We aspire to help people live better, healthier lives. We focus on delivering the highest quality laboratory information through our unique Medical Leadership model and federated structure, through regional diagnostic laboratories operating across the United States.

Since its establishment in 2007, Sonic Healthcare USA has grown to become the third largest laboratory medicine company in the United States, with operations across the country. From our boardroom to our individual practices, we are guided by the leadership of our medical specialists, senior scientists experienced managers, all of whom understand the unique demands and privileges of working to improve the health of our patients. 

Coronavirus Disease 2019 (COVID-19)

Sonic Healthcare USA Expanding Testing Capabilities by Launching COVID-19 Antibody Testing

Austin, TX – April 28, 2020

Sonic Healthcare USA's network of clinical laboratories has begun performing antibody testing for SARS-CoV-2 (COVID-19) to complement our existing molecular PCR testing. 

Sonic Healthcare USA laboratories are initially offering serology testing for SARS-CoV-2 designed to detect IgG and IgA antibodies for patients who are suspected or confirmed of having been exposed to the virus, which causes the coronavirus disease (COVID-19).  The tests are being offered for use under the FDA Emergency Use Authorization (EUA).

"Our COVID-19 Medical and Technical Advisory Taskforce has worked hard to develop guidance for our test development and platform strategy to ensure we can support our local medical communities with their testing needs,” said Jerry Hussong, MD, MBA, the Chief Executive Officer of Sonic Healthcare USA. "It is important to reiterate that results from antibody testing should not be used as the sole basis to diagnose or exclude SARs-CoV-2 infection or to inform infection status or immunity.  Follow-up, concurrent or alternative testing with molecular diagnostic testing should be considered for patient management if clinically indicated,” added Dr. Hussong.

Sonic Healthcare USA continues to collaborate with its supply chain vendors to increase testing capacity and platforms to align with projected demand.  We are committed to partnering with our local medical communities and public health officials and to be a leader in testing and transitional planning for return to work strategies over the coming weeks to mitigate this pandemic. Read More